Abstract
Fragment-based screening is an emerging technology which is used as an alternative to high-throughput screening (HTS), and often in parallel. Fragment screening focuses on very small compounds. Because of their small size and simplicity, fragments exhibit a low to medium binding affinity (mM to μM) and must therefore be screened at high concentration in order to detect binding events. Since some issues are associated with high-concentration screening in biochemical assays, biophysical methods are generally employed in fragment screening campaigns. Moreover, these techniques are very sensitive and some of them can give precise information about the binding mode of fragments, which facilitates the mandatory hit-to-lead optimization. One of the main advantages of fragment-based screening is that fragment hits generally exhibit a strong binding with respect to their size, and their subsequent optimization should lead to compounds with better pharmacokinetic properties compared to molecules evolved from HTS hits. In other words, fragments are interesting starting points for drug discovery projects. Besides, the chemical space of low-complexity compounds is very limited in comparison to that of drug-like molecules, and thus easier to explore with a screening library of limited size. Furthermore, the “combinatorial explosion” effect ensures that the resulting combinations of interlinked binding fragments may cover a significant part of “drug-like” chemical space. In parallel to experimental screening, virtual screening techniques, dedicated to fragments or wider compounds, are gaining momentum in order to further reduce the number of compounds to test. This article is a review of the latest news in both experimental and in silico virtual screening in the fragment-based discovery field. Given the specificity of this journal, special attention will be given to fragment library design.
Keywords: Biophysical screening, computational chemistry, fragment-based drug design, fragment-based drug discovery, library design, high-throughput screening, combinatorial explosion, chemical tractability, diversity, solubility, highaffinity ligands
Combinatorial Chemistry & High Throughput Screening
Title: Fragment-Based Drug Design: Computational and Experimental State of the Art
Volume: 14 Issue: 6
Author(s): Laurent Hoffer, Jean-Paul Renaud and Dragos Horvath
Affiliation:
Keywords: Biophysical screening, computational chemistry, fragment-based drug design, fragment-based drug discovery, library design, high-throughput screening, combinatorial explosion, chemical tractability, diversity, solubility, highaffinity ligands
Abstract: Fragment-based screening is an emerging technology which is used as an alternative to high-throughput screening (HTS), and often in parallel. Fragment screening focuses on very small compounds. Because of their small size and simplicity, fragments exhibit a low to medium binding affinity (mM to μM) and must therefore be screened at high concentration in order to detect binding events. Since some issues are associated with high-concentration screening in biochemical assays, biophysical methods are generally employed in fragment screening campaigns. Moreover, these techniques are very sensitive and some of them can give precise information about the binding mode of fragments, which facilitates the mandatory hit-to-lead optimization. One of the main advantages of fragment-based screening is that fragment hits generally exhibit a strong binding with respect to their size, and their subsequent optimization should lead to compounds with better pharmacokinetic properties compared to molecules evolved from HTS hits. In other words, fragments are interesting starting points for drug discovery projects. Besides, the chemical space of low-complexity compounds is very limited in comparison to that of drug-like molecules, and thus easier to explore with a screening library of limited size. Furthermore, the “combinatorial explosion” effect ensures that the resulting combinations of interlinked binding fragments may cover a significant part of “drug-like” chemical space. In parallel to experimental screening, virtual screening techniques, dedicated to fragments or wider compounds, are gaining momentum in order to further reduce the number of compounds to test. This article is a review of the latest news in both experimental and in silico virtual screening in the fragment-based discovery field. Given the specificity of this journal, special attention will be given to fragment library design.
Export Options
About this article
Cite this article as:
Hoffer Laurent, Renaud Jean-Paul and Horvath Dragos, Fragment-Based Drug Design: Computational and Experimental State of the Art, Combinatorial Chemistry & High Throughput Screening 2011; 14 (6) . https://dx.doi.org/10.2174/138620711795767884
DOI https://dx.doi.org/10.2174/138620711795767884 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Ferulic Acid in Alzheimer's Disease
Current Drug Delivery Folic Acid, Neurodegenerative and Neuropsychiatric Disease
Current Molecular Medicine Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics
Mini-Reviews in Medicinal Chemistry Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents A Rationale for Inhibiting Progesterone-Related Pathways to Combat Breast Cancer
Current Cancer Drug Targets Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design Oxidants in Asthma and in Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
Current Alzheimer Research Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Angiogenesis New Targets for the Development of Anticancer Chemotherapies
Current Pharmaceutical Design Modulation of Alzheimers Amyloidosis by Statins: Mechanisms of Action
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Vascular Stiffness: Measurements, Mechanisms and Implications
Current Vascular Pharmacology A Rationale for Curcuminoids for the Prevention or Treatment of Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Thermodynamics and Electro-Biologic Prospects for Therapies to Intervene in Cancer Progression
Current Cancer Therapy Reviews Dual Acting Antihistaminergic Agents
Mini-Reviews in Medicinal Chemistry Update on the Imaging Techniques in the Diagnosis of Diabetic Retinopathy
Current Diabetes Reviews Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy A Therapeutic Connection between Dietary Phytochemicals and ATP Synthase
Current Medicinal Chemistry